Udifitimod

DB19053InvestigationalSmall molecule

Udifitimod is under investigation in clinical trial NCT05014438 (A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis).

Mechanism: Pharmacologically active on Sphingosine 1-phosphate receptor 1
Curator reviewed
Formula / weight: C₂₅H₃₃NO₂ · 379.544 g/mol (avg)
Also known as: ((1R,3S)-1-amino-3-((S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol · [(1R,3S)-1-amino-3-{(6S)-6-[2-(2-methoxyphenyl)ethyl]- 5,6,7,8-tetrahydronaphthalen-2-yl}cyclopentyl]methanol · Cyclopentanemethanol, 1-amino-3-((6s)-5,6,7,8-tetrahydro-6-(2-(2-methoxyphenyl)ethyl)-2-naphthalenyl)-, (1r,3s)-
Code names: BMS-986166

Resolves to

Compound

UNII283FTA936DCAS1883345-06-9ChEMBLCHEMBL4649457

Structure

InChIKeyQCMHGCDOZLWPOT-FMNCTDSISA-NSMILESCOC1=CC=CC=C1CC[C@@H]1CCC2=CC(=CC=C2C1)[C@H]1CC[C@](N)(CO)C1

Targets

P21453S1PR1

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Udifitimod, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account